24  -0.17 (-0.7%)		12-11 15:59
Open: 24.22 High: 24.225 Volume: 40,095		Pre. Close: 24.1701 Low: 24 Market Cap: 139(M)

Short term
Mid term
Targets	6-month :	28.74	1-year :	30.13
Resists	First :	24.6	Second :	25.79
Pivot price	24.11
Supports	First :	22.68	Second :	18.86
MAs	MA(5) :	24.22	MA(20) :	23.96
	MA(100) :	24.39	MA(250) :	23.81
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	65	D(3) :	71.5
RSI	RSI(14): 46.5
52-week	High :	25.79	Low :	21.53

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ IDNA ] has closed above bottom band by 43.5%. Bollinger Bands are 4.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	24.28 - 24.42	24.42 - 24.53
Low:	23.65 - 23.84	23.84 - 23.99
Close:	23.74 - 24.03	24.03 - 24.24

The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.

Wed, 13 Nov 2024
Future Health: Harnessing Innovations In Healthcare - Syfe

Thu, 04 Jan 2024
Has Biotechnology Bottomed Out? - Master Investor

Mon, 25 Dec 2023
3 Healthcare Technology Stocks to Improve Lives in 2024 - InvestorPlace

Thu, 08 Jun 2023
IDNA: Continues To Underperform, But With Long-Term Potential - Seeking Alpha

Mon, 17 Apr 2023
Megatrends: Gene Therapy and Editing - U.S News & World Report Money

Fri, 14 Apr 2023
StockWatch: Top Biotech ETFs (Mostly) Sink Faster than the Market During Q1 - Genetic Engineering & Biotechnology News

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Financial Services
Industry: Asset Management
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.